Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options
- Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetesCompany announcement – No. 54 / 2026
- Lipocine Inc.Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement TherapyLipocine Inc. (NASDAQ: LPCN ), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or abse
- Hagens Berman Sobol Shapiro LLPAARD 6-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff DeadlineHagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: $AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
- FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic ConditionPotentially accelerates development, assessment, and review for approval by FDA
- Halia TherapeuticsHalia Therapeuticsto Participate in the 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 ForumHalia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to participate in the 6th Annual Needham Private Biotech...
- MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerEnrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
- Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate FieldNIJMEGEN, The Netherlands – 7 October 2026 – Byondis B.V., a private biopharmaceutical company engineering antibody-drug conjugates (ADCs) to tackle the cancers that current therapies cannot reach, will share progress from its platform technology portfolio at World ADC San Diego, the world's largest ADC conference, being held from 12-15 October in San Diego, USA.
- VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsAs the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
- Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS
- Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Renata has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
- AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced an oral presentation at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. The presentation will feature new data from AltruBio’s Phase 2a ASCEND UC2a trial (NCT06109441) evaluating its lead asset, ALTB-268, in patients with moderately to severely active ulcerative colitis with an inadequate response to prior advanced therapy.